Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

1.

Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.

Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH.

J Cyst Fibros. 2015 Aug 25. pii: S1569-1993(15)00171-X. doi: 10.1016/j.jcf.2015.07.009. [Epub ahead of print]

2.

Optimising inhaled mannitol for cystic fibrosis in an adult population.

Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, Fox HG, Hebestreit H, Kolbe J, Zuckerman JB, Button BM.

Breathe (Sheff). 2015 Mar;11(1):39-48. doi: 10.1183/20734735.021414. Review.

3.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group.

Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.

PMID:
26070913
4.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

PMID:
25981758
5.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA.

Thorax. 2015 Apr 24. pii: thoraxjnl-2014-206750. doi: 10.1136/thoraxjnl-2014-206750. [Epub ahead of print]

PMID:
25911223
6.

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study.

Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA.

J Cyst Fibros. 2015 Feb 25. pii: S1569-1993(15)00040-5. doi: 10.1016/j.jcf.2015.02.003. [Epub ahead of print]

PMID:
25725985
7.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

PMID:
25592656
8.

Clinical applications of pulmonary delivery of antibiotics.

Flume PA, VanDevanter DR.

Adv Drug Deliv Rev. 2015 May;85:1-6. doi: 10.1016/j.addr.2014.10.009. Epub 2014 Oct 22. Review.

PMID:
25453268
9.

A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.

Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF.

Chest. 2014 Aug;146(2):437-48. doi: 10.1378/chest.13-1891. Review. Erratum in: Chest. 2014 Nov;146(5):1422.

PMID:
24626872
10.

Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis?

Hill AT, Flume PA.

Am J Respir Crit Care Med. 2014 Mar 1;189(5):510-1. doi: 10.1164/rccm.201401-0129ED. No abstract available.

PMID:
24579835
11.

Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.

Stenbit AE, Bullington WM, Heh JL, Flume PA.

J Cyst Fibros. 2013 Jul;12(4):403-6. doi: 10.1016/j.jcf.2012.11.007. Epub 2012 Dec 20.

12.

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis.

Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, Fox HG, Gallagher CG, Geller DE, Haarman EG, Hebestreit HU, Kolbe J, Lapey A, Robinson P, Wu J, Zuckerman JB, Aitken ML; CF301 and CF302 Investigators.

J Cyst Fibros. 2013 Jul;12(4):367-76. doi: 10.1016/j.jcf.2012.11.002. Epub 2012 Dec 9.

13.

State of progress in treating cystic fibrosis respiratory disease.

Flume PA, Van Devanter DR.

BMC Med. 2012 Aug 10;10:88. doi: 10.1186/1741-7015-10-88. Review.

14.

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Flume PA, Liou TG, Borowitz DS, Li H, Yen K, OrdoƱez CL, Geller DE; VX 08-770-104 Study Group.

Chest. 2012 Sep;142(3):718-24.

15.

Chronic cystic fibrosis respiratory infections: where do we go from here? Introduction.

Flume PA.

Respir Med. 2011 Dec;105 Suppl 2:S1. doi: 10.1016/S0954-6111(11)00444-6. No abstract available.

16.

Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis.

VanDevanter DR, Ballmann M, Flume PA.

Respir Med. 2011 Dec;105 Suppl 2:S18-23. doi: 10.1016/S0954-6111(11)70023-3.

17.

Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.

Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B; CF302 Investigators.

Am J Respir Crit Care Med. 2012 Mar 15;185(6):645-52. doi: 10.1164/rccm.201109-1666OC. Epub 2011 Dec 28.

PMID:
22198974
18.

Prerenal azotemia from excessive sweating in an adult with a cystic fibrosis gene mutation.

Tomov SV, Flume PA, Stenbit AE, Ullian ME.

Indian J Nephrol. 2011 Jul;21(3):194-7. doi: 10.4103/0971-4065.82637.

19.

Pulmonary exacerbations in cystic fibrosis.

Stenbit AE, Flume PA.

Curr Opin Pulm Med. 2011 Nov;17(6):442-7. doi: 10.1097/MCP.0b013e32834b8c04. Review.

PMID:
21881509
20.

Update in cystic fibrosis 2010.

Mogayzel PJ Jr, Flume PA.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1620-4. doi: 10.1164/rccm.201102-0275UP. Review. No abstract available.

PMID:
21693717
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk